Saturday, August 23, 2025

Latest

Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies

Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being conducted by the firm. The company has seen efficacy in rodent models of Dravet Syndrome, a form of epilepsy, within ongoing late pre-clinical trials.

The efficacy was seen in what the company refers to as its 5-HT2C agonist, BMB-101. The compound is referred to as a novel, well-characterized highly selective agonist, which was originally developed by the firms Chief Scientific Officer.

“These early positive results around the antiseizure effects of BMB-101 and other analogues are very encouraging and further reinforce the potential of serotonin (5-HT2C) agonists to address difficult to treat developmental and genetic epilepsies, including Dravet Syndrome and Lennox-Gastaut Syndrome (“LGS”),” said Ian McDonald on the results, whom is CEO of the firm.

The compound itself was studied in three separate models as part of the firms pre-clinical study. The first study, referred to as a Scn1Lab zebrafish model, reportedly mimics clinical hallmarks of Dravet syndrome, with similar experiments using the model shown to have successfully predicted the clinical efficacy of drugs against the syndrome.

In layman terms, other models conducted by the firm demonstrated a 74% decrease in seizure duration one hour after injection of the compound into rodents, while a “significant number” of the subjects were reportedly completely protected from seizures. Further, at the highest dosage administered, all rats were protected from seizures administered via the maximum electroshock seizure model, which proves promising for the firms proprietary compound.

“BMB-101 is a promising lead candidate to treat Dravet Syndrome patients. The data provide clear evidence that it has a therapeutic effect on the abnormal brain activity of Scn1Lab zebrafish, resulting in pronounced antiseizure activity. The effects of BMB-101 parallel those of other anti-epileptics, such as fenfluramine, a drug marketed for these patients.”

Ian McDonald, CEO

Bright Minds Biosciences last traded at $6.42 on the CSE.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

G Mining Q2 Earnings: Costing Gone Wild

Aya Gold Q2 Earnings: Production Slips Amid Ramp Up

i-80 Gold Q2 Earnings: Better, But Not Great

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022

Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This...

Wednesday, September 22, 2021, 03:24:00 PM

Bright Minds Bioscience Approved For Nasdaq Listing

There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE:...

Wednesday, November 3, 2021, 08:50:22 AM

Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive

On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE:...

Friday, September 10, 2021, 01:30:00 PM

Bright Minds Bioscience: A Deep Dive

Today we are diving into a firm focused on mental health, whom is also a...

Thursday, December 2, 2021, 01:30:00 PM

Bright Minds Biosciences: Corporate Overview

Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to...

Monday, May 31, 2021, 02:43:00 PM